RxDoctor Payments Data

Daksha Mehta, MD

Internal Medicine · Whittier, CANPI 1982622346

Payments from drug & device makers

$321in general payments, 2019–2025

Across 16 payments — averaging $20.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$108
  • GSK$69
  • AstraZeneca$28
  • Pulmonx Corporation$28
  • Boehringer Ingelheim$25
  • Philips North America LLC$24
  • plus $38 from 3 others

What the payments were for

  • Food & beverage$31096%
  • Education$124%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$321 in reported general payments places this provider in the 60th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$63,506
Medicare patients
381
Services billed
868

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate34$424,976
Trelegy ElliptaFluticasone/Umeclidin/Vilanter177$128,256
TezspireTezepelumab-Ekko14$81,269
Breo ElliptaFluticasone/Vilanterol158$74,126
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr119$61,319
Spiriva HandihalerTiotropium Bromide69$60,854
Advair HfaFluticasone Propion/Salmeterol127$44,007
Wixela InhubFluticasone Propion/Salmeterol324$42,806
SymbicortBudesonide/Formoterol Fumarate143$41,431
Fluticasone-SalmeterolFluticasone Propion/Salmeterol211$35,394
Albuterol Sulfate HfaAlbuterol Sulfate711$20,179
Spiriva RespimatTiotropium Bromide30$18,333
Incruse ElliptaUmeclidinium Bromide44$17,665
Qvar RedihalerBeclomethasone Dipropionate45$17,334
BreynaBudesonide/Formoterol Fumarate110$16,416

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat, Stiolto Respimat$25$467,58895 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$69$296,208566 claims
AstraZenecaTezspire, Symbicort$28$122,700157 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Whittier

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →